NorthStar Medical Technologies Raises $185 Million
NorthStar Medical Technologies, a radiopharmaceutical company based in Madison, Wisconsin, has announced a significant growth financing round. The company, which specializes in developing innovative solutions to detect and treat cancer and other serious diseases, secured $185 million from Hercules Capital.
Details of the Growth Round
This latest financing is structured as a multi-year growth capital facility. According to the company, $100 million of the funds will be available upfront. The capital injection will primarily support the expansion of NorthStar's production capabilities for no-carrier-added Actinium-225 (Ac-225), an isotope crucial for targeted alpha therapies for cancer.
Expansion Plans
NorthStar intends to use the funds to increase isotope production and enhance its clinical and commercial drug manufacturing infrastructure at its integrated radiopharmaceutical campus. The company plans to transition to a higher-capacity Ac-225 production line later in 2026. This expansion is expected to meet the growing demand from pharmaceutical and biotechnology customers, including over 30 companies currently engaged in supply and manufacturing agreements with NorthStar.
Industry Impact
Frank Scholz, President and CEO of NorthStar, emphasized the company's strategic role in the radiopharmaceutical industry. "This commitment from Hercules provides the necessary capital to expand our capacity, accelerate our growth, and support our partners as they advance innovative therapies to patients across the world," Scholz stated.
Hercules Capital's Managing Director, Lake McGuire, also commented on the funding, noting NorthStar's ability to produce critical isotopes at a pivotal time for the industry.
Regulatory Milestones
In addition to its production expansion, NorthStar has achieved a regulatory milestone with the FDA's acceptance of its Drug Master File for no-carrier-added Ac-225. This acceptance provides a regulatory pathway for incorporating the isotope into clinical and commercial radiopharmaceutical programs, further solidifying NorthStar's position as a key supplier in the industry.
Conclusion
As NorthStar Medical Technologies continues to expand its capabilities and partnerships, the company is well-positioned to support the growing needs of the radiopharmaceutical market, aiding in the development of innovative cancer therapies.